EGFR and metastatic colorectal cancer: In metastatic colorectal cancer (mCRC), treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab or panitumumab has demonstrated efficacy in wild-type (WT) RAS mutations and it is now considered imperative this determination at the time of diagnosis [1, 2].